KBI Biopharma vs Novartis: CDMO Comparison

How does KBI Biopharma compare to Novartis?

As of Mar 2026, KBI Biopharma: 2 FDA inspections (including 0 NAI, 2 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 84.1. Novartis: 17 FDA inspections (including 9 NAI, 8 VAI and 0 OAI), 51 EMA/MHRA GMP certificates. Signal Score 85.4. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of KBI Biopharma and Novartis on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Durham, NC · Boulder, CO
Signal Score
84/100
Quality (FDA + GMP)
98/100
FDA inspections
2
— NAI / VAI / OAI
0 / 2 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Limited
Modalities
Monoclonal Antibody, Recombinant Protein, AAV (analytical only), Plasmid DNA
Basel, Switzerland
Signal Score
85/100
Quality (FDA + GMP)
97/100
FDA inspections
17
— NAI / VAI / OAI
9 / 8 / 0
FDA warning letters
0
EMA GMP certificates (active)
50
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
137
Capacity
—
Modalities
CAR-T, Gene Therapy

Key differences

  • Novartis has more FDA inspections on record (17 vs 2) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Novartis holds 50 active EMA GMP certificates; KBI Biopharma does not appear in EudraGMDP.
  • Novartis appears as a manufacturing partner on more matched clinical programs (137 vs 0) — a broader sponsor book.

Across the cross-modality scorecard, Novartis carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: KBI Biopharma vs Novartis

How does KBI Biopharma compare to Novartis?

On CDMO Signal's composite Signal Score, KBI Biopharma is 84/100 and Novartis is 85/100; KBI Biopharma has 2 FDA inspections on record vs 17 for Novartis; European coverage is 1 active EMA+MHRA certificate for KBI Biopharma vs 51 for Novartis. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, KBI Biopharma or Novartis?

Both KBI Biopharma and Novartis maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. KBI Biopharma has 2 FDA inspections on record; Novartis has 17.

How do KBI Biopharma and Novartis compare on European GMP coverage?

KBI Biopharma holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Novartis holds 50 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — KBI Biopharma or Novartis?

KBI Biopharma is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Novartis is matched to 137. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

What does the Signal Score gap mean in practice?

KBI Biopharma carries a Signal Score of 84/100 and Novartis carries 85/100 — essentially tied for Novartis. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating KBI Biopharma and Novartis for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.